SCHEMBL273928

SCHEMBL273928

O=C(O)CN1CCN(CC(=O)O)CC(=O)N(CC(=O)O)CC1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.42
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 2/20 0.41
POLB P06746 1/20 0.41
CYP2C9 P11712 1/20 0.41
KMT2A Q03164 1/20 0.41
ITGB3 P05106 3/20 0.40
ITGA2B P08514 3/20 0.40
ACE P12821 2/20 0.39
LMNA P02545 1/20 0.38
SLC6A9 P48067 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7140993 0.98 CYP2D6 (0.42) HSD17B10CYP2D6CYP2C19POLBCYP2C9
SCHEMBL8019441 0.82 HSD17B10 (0.34) HSD17B10CYP2D6CYP2C19POLBCYP2C9
SCHEMBL7139127 0.82 CYP2D6 (0.37) CYP2D6CYP2C19POLBCYP2C9KMT2A
SCHEMBL30875935 0.82 ITGB3 (0.43) CYP2D6CYP2C19POLBCYP2C9KMT2A
SCHEMBL3489028 0.80 S1PR1 (0.41) HSD17B10POLBTSHR
SCHEMBL23291471 0.79 KMT2A (0.63) CYP2D6CYP2C19POLBCYP2C9KMT2A
SCHEMBL23291436 0.79 CYP2D6 (0.63) CYP2D6CYP2C19POLBCYP2C9KMT2A
SCHEMBL30875934 0.77 PTGS1 (0.41) CYP2D6CYP2C19POLBCYP2C9KMT2A
SCHEMBL30875932 0.77 PTGS1 (0.41) CYP2D6CYP2C19POLBCYP2C9KMT2A
SCHEMBL2544936 0.77 PIK3CD (0.55) HSD17B10POLBKMT2ASLC6A9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2249967-B1 OXIDIZED AND MALEATED DERIVATIVE COMPOSITION INGEVITY SOUTH CAROLINA LLC (US) 2019-03-13 EP disclosed
US-8133970-B2 Oxidized and maleated derivative compositions GEORGIA-PACIFIC CHEMICALS LLC (US) 2012-03-13 US disclosed
EP-2170277-A1 CHEMICAL MODIFICATION OF MALEATED FATTY ACIDS Georgia-Pacific Chemicals LLC (US) 2010-04-07 EP disclosed
US-20090194731-A1 OXIDIZED AND MALEATED DERIVATIVE COMPOSITIONS GEORGIA-PACIFIC CHEMICALS LLC (US) 2009-08-06 US disclosed
US-20090065736-A1 CHEMICAL MODIFICATION OF MALEATED FATTY ACIDS GEORGIA-PACIFIC CHEMICALS LLC (US) 2009-03-12 US disclosed
WO-2009006527-A1 CHEMICAL MODIFICATION OF MALEATED FATTY ACIDS GEORGIA-PACIFIC CHEMICALS LLC (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090194731-A1 OXIDIZED AND MALEATED DERIVATIVE COMPOSITIONS FASN, TKFC, ELOVL5 HSD17B10 672/4885CYP2D6 888/4885CYP2C19 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.